Examining and comparing the effect of zintoma versus ondansetro
Phase 3
- Conditions
- ausea and vomiting.haematemesis (K92.0)haematemesisneonatal (P54.0)vomiting (of):excessive, in pregnancy (O21.-)following gastrointestinal surgery (K91.0)newborn (P92.0)psychogenic (F50.5)R11. 2
- Registration Number
- IRCT20231010059683N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 128
Inclusion Criteria
Patients undergoing chemotherapy
Children over 6 years old
Exclusion Criteria
Heavy chemotherapy
Discontinuation of chemotherapy for any reason
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome: treatment response which includes: presence/absence of chemotherapy-related nausea and vomiting. Timepoint: 3 days after treatment. Method of measurement: patient file; patient question.
- Secondary Outcome Measures
Name Time Method Secondary outcome: patient's appetite after treatment. Timepoint: 3 days After treatment. Method of measurement: by Asking the patient.